To report the oncological outcome of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after external beam radiotherapy (EBRT) from a multicentre database.
Introduction
A significant proportion of patients experience a recurrence after external beam radiotherapy (EBRT) [1, 2] . The recurrence rate after EBRT at 5 years in a multicentre study was reported to be 39% and 28% for 70 and 80 Gy, respectively [3] . After intensity-modulated RT, with a median dose of 7.6 Gy, biochemical survival rates at 9 years were 77.4%, 69.6% and 53.3% for low-, intermediate-and high-risk patients, respectively [4] . In the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) population, >90% of patients with recurrent prostate cancer received palliative androgen-deprivation therapy (ADT), which suppresses PSA levels but with absolutely no chance of cure [5] . Salvage radical prostatectomy (SRP) series have reported 10-year biochemical failure-free (bFFS), metastasis-free (MFS), and cancer-specific (CSS) survival probabilities of 37%, 77%, and 83%, respectively [6] . However, SRP is associated with significant morbidity especially urinary incontinence [7] .
High-intensity focused ultrasound (HIFU) has been used as a primary treatment for prostate cancer for over a decade [8] [9] [10] . More recently, the technology was evaluated as a salvage therapy for locally recurrent prostate cancer after EBRT in patients without evidence of metastasis [11] . Based on data from 290 consecutive patients, the 7-year estimated CSS rate after salvage HIFU (S-HIFU) was 80%. The progression freesurvival rates were 53%, 42% and 25% for low-, intermediate-, and high-risk patients (D'Amico), respectively, suggesting that S-HIFU is a valuable therapy for radio-recurrent prostate cancer [12] . S-HIFU is intended to completely ablate all prostate tissue that remains after primary EBRT. In the present multicentre, registry study, we evaluated the oncological outcomes and the associated morbidity of S-HIFU along with the preoperative prognostics that predict oncological success for the first time in a large cohort.
Patients and Methods
The Ablatherm (EDAP-TMS, Lyon, France) treatment registry (@-Registry TM ) is a secure on-line database for patients who have undergone prostate HIFU using the Ablatherm device. The @-Registry was specifically designed to collect de-identified pre-and post-treatment information. Data from 3218 consecutively treated patients entered in the @-Registry between December 2005 and June 2009 were reviewed for this retrospective analysis.
Patients who underwent total gland S-HIFU for locally recurrent prostate cancer (T1-2) after EBRT were included in the analysis. The inclusion criteria were a biochemical failure [American Society for Therapeutic Radiology and Oncology (ASTRO) before 2006 and then Phoenix definition) [13, 14] , a positive post-EBRT biopsy, and a negative metastatic evaluation. Metastatic evaluation included a bone scan and an abdominopelvic CT, and most patients also received a prostatic MRI. All patients who received ADT within 90 days of S-HIFU were excluded from the analysis.
Contraindications for S-HIFU included anal/rectal stenosis and a rectal wall thickness >6 mm measured in by TRUS.
Total gland S-HIFU was performed using the Ablatherm HIFU device. The prostate was treated in two to four overlapping blocks from the apex to the base. Between 1995 and March 2002, standard treatment parameters were used. This entailed 100% acoustic power with a 6-s pulse of energy to create each discrete HIFU lesion with a 4-s delay between each shot. Starting in March 2002, specific post-RT parameters were adopted (4-s pulse, 6-s waiting period, 90% of the acoustic power) due to the high rate of morbidity with the protocol before 2002. These were developed considering the decreased vascularity of the previously irradiated tissue. The goal was to optimise the thermal dose delivered within the gland while minimising the possible damage probability to surrounding tissues, especially the rectal wall, which is caused by conductive heat transfer.
S-HIFU treatments were usually performed under spinal anaesthesia or general anaesthesia. Most of the patients underwent a bladder neck incision to reduce the risk of urinary retention and BOO after S-HIFU. TURP was performed if a median lobe was present. TURP and S-HIFU were performed during a single session, and patients were usually discharged from hospital 3-5 days after the procedure with or without a urinary catheter. No adjuvant ADT was used after S-HIFU.
Patient follow-up included clinical and biochemical evaluations every 3 months for the first year and every 6 months thereafter. Initially, treated patients first underwent systematic biopsies at 3 months. Additional biopsies were taken in cases of rising PSA during follow-up. Since 2008, when the PSA nadir was <0.2 ng/mL, systematic control biopsies have not taken [15] . Control biopsies were taken only in cases of rising PSA. A complete diagnostic evaluation was conducted in cases of biochemical relapse after S-HIFU. A second S-HIFU session was offered when an exclusively local recurrence was identified. Side-effects were systematically evaluated and recorded. Urinary incontinence was graded according to the Ingelman-Sundberg score (strong, moderate, minimal effort: grade I, grade II and grade III, respectively) [16] .
The CSS, MFS and bFFS rates were estimated using the Kaplan-Meier method. Biochemical failure was defined as an increase of ≥2 ng/mL above the PSA nadir (Phoenix definition) [14] . The salvage treatment-free survival rate was defined as the time of ADT initiation. The bFFS was stratified according to the pre-radiotherapy D'Amico's risk group, the pre-S-HIFU PSA level (≤4, 4.1-10, or >10 ng/mL), the pre-S-HIFU estimated Gleason score (≤6, 7, ≥8) and the administration of ADT prior or during EBRT. The KaplanMeier method was also used to estimate the bFFS curves according to the different categories of each factor compared when using the log-rank test. A Cox model was used for multivariate analysis to identify independent factors linked to the risk of failure. Analysis was performed using the statistical software S-plus version 6.2. A P < 0.05 was chosen to identify statistically significant differences.
Results
Of the 3218 datasets collected in the @-Registry between December 2005 and June 2009, 418 patients met the inclusion criteria for the analysis ( Table 1 ). The mean (SD) RT dose was 69.2 (6.5) Gy (median 70 Gy) and the mean (SD) time between EBRT and S-HIFU was 5.1 (2.7) years. The mean (SD) age at S-HIFU was 68.6 (5.8) years and the PSA level before S-HIFU was 6.8 (7.8) ng/mL. In all, 191 patients (45.7%) had a history of ADT (neoadjuvant, concomitant or adjuvant). No patients continued ADT after S-HIFU treatment.
The mean (SD) prostate volume before S-HIFU was 20.6 (7.9) mL and the treated volume was 22.2 (8.5) mL (average 108% of the prostate volume due to an overlap between the treated zone inside the prostate). The total number of S-HIFU sessions was 476 [one session: 364 (87.1%), two sessions: 51 (12.2%), and three sessions: three (0.7%)].
The median (range) follow-up after S-HIFU was 3.3 (1.5-5.2) years. The mean (SD) prostate volume after S-HIFU was 15.0 (8.8) mL. Due to the small prostate volume after S-HIFU, a minimum of six control biopsies were usually taken to evaluate the local control of the prostate cancer. In all, 254 patients (60.8%) underwent biopsy of which 187 (73.6%) were negative. Of the 164 patients without control biopsy, 88 (53.6%) did not have biochemical recurrence, while 76 (46.4%) did and were placed on ADT.
The mean (SD) PSA nadir was 1.9 (5.2) ng/mL (median 0.19, range 0-54.9 ng/mL) and was reached at a mean (SD) time of 10.1 (10.7) weeks after S-HIFU. In all, 225 patients (53.8%) reached a nadir PSA level of ≤0.3 ng/mL and 203 (48.6%) ≤0.2 ng/mL.
In all, 222 patients (53.1%) did not receive any salvage treatment after S-HIFU, while 196 patients (46.9%) received ADT for recurrent local prostate cancer or metastases after S-HIFU. Of the 196 patients that received ADT after S-HIFU, 45 (23%) had positive biopsies, 75 (38.3%) had negative biopsies, and 76 (38.8%) did not have biopsies taken. Of the 222 patients that did not receive ADT after S-HIFU, 22 (9.9%) had positive biopsies, 112 (50.5%) had negative biopsies, and 88 (39.6%) did not have biopsies taken. The OS, CSS and MFS rates at 7 years were 72%, 82% and 81%, respectively ( Fig. 1 ).
The bFFS rate at 5 years was 49%. At 5 years the bFFS rate was 58%, 51% and 36% for pre-EBRT low-, intermediate-and high-risk patients, respectively. The 5-year bFFS rate was 67%, 42% and 22% for pre-S-HIFU PSA levels of ≤4, 4-10 and ≥10 ng/mL respectively and 59%, 41% and 39% for pre-S-HIFU Gleason score of ≤6, equal to 7 and ≥8, respectively. The bFFS rate was 59% for patients without any previous ADT and 38% for those with a history of ADT (Fig. 2) .
The salvage treatment-free survival rate at 5 years was 37%, and was 54%, 37% and 23% for pre-EBRT low-, intermediateand high-risk patients, respectively. The 5-year salvage treatment-free survival rate was 49%, 33% and 20% for pre-S- HIFU PSA levels of ≤4, 4-10 and ≥10 ng/mL respectively and 50%, 38% and 22% for pre-S-HIFU Gleason score of ≤6, equal to 7 and ≥8, respectively. The 5-year salvage treatmentfree survival rate for patients without any previous ADT was at 48% vs 26% for those with a history of ADT (Fig. 3) .
In the multivariate analysis three factors (history of ADT, pre-S-HIFU Gleason score and pre-S-HIFU PSA level) were significantly linked to biochemical recurrence and initiation of a salvage treatment ( Table 2 ).
The PSA nadir was a major predictive factor for salvage treatment-free survival rate (Fig. 3) . The salvage treatmentfree survival rate at 5 years was 56%, 16% and 8% for PSA nadir of ≤0.3, 0.31-1 and >1 ng/mL, respectively.
The specific post-RT parameters introduced in 2002 decreased the rate of many long-term complications (Table 3 ). Moderate and severe incontinence (grade II or III) decreased from 32% to 19%. The incidence of artificial urinary sphincter implantation was significantly reduced with the specific post-RT parameters when compared to standard parameters (15% vs 5%; P < 0.001). The incidence of BOO or stenosis incidence dropped from 30% to 15% (P = 0.001).
The rate of recto-urethral fistula decreased from 9% to 0.6%. Erectile function was not evaluated. Of the nine recto-urethral fistulae, only two were successfully closed with a YorkMasson procedure. The other seven, were managed with colostomy and Bricker (four) or colostomy alone (three). Osteitis was managed with prolonged antibiotics in six patients, retropubic muscular interposition in two, colostomy and Bricker in one.
Discussion
Most men with radio-recurrent prostate cancer are treated with systemic ADT [5, 17] . ADT is also associated with adverse effects, including cardiac and thromboembolic complications [18] . Patients treated with ADT or ADT followed by chemotherapy have poor outcomes. In the Zumsteg et al. [19] study, the date of biochemical failure to distant metastasis and cancer-specific mortality were 5.4 and 10.5 years respectively, despite the use of medical therapies, the estimated 5-year post-biochemical failure distant metastasis rate was 47% and the 5-year cumulative incidence of cancer-specific mortality was 18%. In our present study, after S-HIFU, the estimated MFS rate was 81% at 7 years.
The CSS rate after SRP at 10 years was reported to be 77% [20] . More recently, in a series of 404 patients undergoing SRP, at 10 years, the bFFS rate was 37%, the MFS rate was 77% and the CSS rate was 83% [6] . Definitive surgery for local recurrent prostate cancer after EBRT is associated with severe morbidity. The average rate of rectal injury was 4-7%, of bladder neck stricture was 24%, and the average urinary incontinence rate was 41% [21] . In a recent study, the rate of urinary incontinence was found to be 45.5% with 25.5% using 1 pad/day and 20% with ≥2 pads/day [7] . The rate of rectal injury was 3.6%. Those survival and complication data seem similar to those achieved with S-HIFU. But if only patients with specific S-HIFU parameters are evaluated, S-HIFU compares favourably with SPR. Results achieved after a robotic procedure seem similar to those of open surgery. In 2013, Yu et al. [22] reported complications and oncological outcomes of 51 robot-assisted SRPs: the estimated 3-year bFFS or progression-free survival rate was 57%. The overall complications rate was 47% with a 35% major complications rate (Clavien-Dindo III-V): 16% bladder neck contractures, 4% thromboembolic events and 4% urosepsis. Return to urinary continence was achieved in 45% of patients.
Salvage cryotherapy is another option for this patient group. The disease-free survival rate at 10 years was 39% and the CSS rate was 87% in a report by Williams et al. [21] . The predictive factors of recurrence for salvage cryotherapy and for S-HIFU are similar (pre-salvage treatment PSA level, Gleason score, and PSA nadir). The morbidity for salvage cryotherapy is significant: recto-urethral fistula, 1-2%; obstruction/retention, 3.2-67%; chronic perineal pain, 4-14%; severe incontinence, 2-4%; and mild incontinence, 6-13% [23, 24] .
One concern with the localisation of the recurrence after EBRT is the localisation close to the urethra. Leibovici et al. [25] found 74% of recurrences are located within 5.0 mm of the urethra. The advantage of S-HIFU is the complete treatment without preservation of the urethra as opposed to cryotherapy.
Pisters et al. [26] compared the treatment outcomes of SRP and salvage cryotherapy for patients with locally recurrent prostate cancer after initial RT. Compared to salvage cryotherapy, SRP resulted in superior biochemical survival. In previously reported data, the progression-free survival rates after salvage cryotherapy at 5 years ranged from 40% [27] to 59% [28] .
Few data are available for salvage brachytherapy with short follow-ups. The rate of morbidity was found on average for *Pre-EBRT risk was not significant and was removed from the model (Cox backward stepwise method). incontinence to be 36%, recto-urethral fistula 3.4% and rectal grade 3-4 toxicity 5.6% [29] . Gomez-Veiga et al. [30] reported the main results of 10 trials of salvage brachytherapy for EBRT failure: the 5-year biochemical disease-free survival (bDFS) rates ranged from 20% to 87%. One study reported a 10-year bDFS rate of 54%. The incidence of gastrointestinal complications ranged from 5.4% to 65% and 2.7% to 20% for grade 1-2 and grade 3-4 complications, respectively.
In the present analysis, we evaluated survival rates after S-HIFU therapy for locally radio-recurrent prostate cancer in the largest case series to date. At a mean follow-up of 7 years after S-HIFU, the CSS and MFS rates were 72% and 82%, respectively. Our present results appear similar to those obtain after salvage surgery with a lower rate of severe complications using specific post-RT S-HIFU parameters. The present results support the use of S-HIFU as a definitive treatment for local recurrence after EBRT. Another series of S-HIFU performed with the Sonablate â device with a shorter follow-up (19.8 months) found a bFFS rate at 2 years of 43%, with 62% of patients being pad free [31] . The rate of BOO was 20% and the rate of recto-urethral fistula was 2.4% after one treatment.
In 2002, treatment-specific parameters for post-RT S-HIFU with Ablatherm â device were introduced to account for the vascularisation of the prostate gland and peri-prostatic tissue, resulting from RT-induced fibrosis. The incidence of sideeffects dropped significantly when the dedicated acoustic parameters of the S-HIFU device were implemented. With the latest Ablatherm device the rate of recto-urethral fistula is now <1% and the rate of severe incontinence is <20%. These data compare favourably with recent data on salvage surgery [7] . The main side-effect in our present series was BOO caused by urethral stricture, bladder neck stenosis or an accumulation of captive necrotic tissue in the treated area. The decrease of BOO achieved with dedicated parameters is probably due to reduction of the shots duration and acoustic intensity (i.e. thermal dose).
An important prognostic factor was the pre-S-HIFU PSA level, which can serve as a very early identifier of local recurrence after EBRT. This suggests that, to increase the chances of a successful treatment, control biopsies should be taken as soon as a biochemical relapse is identified. The pre-S-HIFU estimated Gleason score and previous ADT are also predictive factors of success.
Early identification of local recurrence after EBRT allows the option of focal therapy using S-HIFU or salvage cryotherapy [32] . In the Ly et al. [33] study, 91 patients with biopsy confirmed radio-recurrent prostate cancer underwent salvage focal cryoablation with curative intent. The bDFS rates was 46.5% at 5 years, and there were positive biopsies after salvage focal cryoablation in four of 14 patients who underwent biopsy. Recto-urethral fistula occurred in three patients (3.3%), urinary retention in six (6.6%), and incontinence in five (5.5%). In the Ahmed et al. [34] study, 39 patients received focal S-HIFU for localised recurrence after EBRT. The estimated progression-free survival rate was 49% at 2 years according to the Phoenix criteria and the padfree rate was 87.2% at the last follow-up. In the two-centre study of Baco et al. [35] , 48 patients received hemi-S-HIFU for unilateral radio-recurrent prostate cancer. The progression-free survival rate at 24 months was 52% and severe incontinence occurred in 8% of the patients, 17% required 1 pad/day and 75% were pad free. Focal therapies (cryoablation or HIFU) in patients with unilateral radiorecurrent prostate cancer results in less morbidity than whole gland salvage therapies. Accurate imaging and targeted biopsy are essential for identifying patients suitable for focal salvage procedures.
The present study has limitations: it is a retrospective analysis of registry data with a relatively short follow-up period. We did not evaluate PSA-doubling time, and the influence of the interval between EBRT and recurrence. The pre-EBRT D'Amico risk group was unknown in 41.6% of the patients and could represent a bias for the statistical analysis. Furthermore, the absence of a control group could have overestimated the effect of S-HIFU on the salvage treatmentfree survival rate and CSS rate.
The lack of patient-reported outcome measures in the @registry is a drawback for quality of life evaluation. Concerning biochemical failure, the Phoenix definition was used in the present study, although it is not validated for HIFU treatment. To overcome this limitation we presented the results of the salvage treatment-free survival rate after S-HIFU.
In the present retrospective study, the locoregional and metastatic evaluation was not optimal for the first set of patients as positron emission tomography-choline and bone-MRI were not routinely available. Careful patient selection should be performed and the prospect of salvage treatment should be carefully weighed in the absence of level I evidence. Rectal stenosis after EBRT can represent an issue for S-HIFU. An MRI with an endorectal balloon can evaluate the size of the rectum and the rectal wall thickness before treatment.
Nonetheless, these data represent the largest case series of S-HIFU after RT failure to date, and the CSS, MFS and bFFS rates, add to the growing body of evidence that supports the expanded use of this procedure.
Conclusion
S-HIFU for locally recurrent prostate cancer after failed EBRT is associated with favourable 7-year survival rates at a price of significant morbidity, which patients should be made aware 902 © 2017 The Authors BJU International © 2017 BJU International of. Longer-term survival rates are needed, although the data presented supports the view that S-HIFU should now be considered as a definitive treatment option for patients with sufficient life expectancy to justify a salvage curative treatment.
